sodium-dodecyl-sulfate and Candidiasis--Vulvovaginal

44 patients with candidal vaginitis participated in a trial using a new formulation of a mepartricin-sodium lauryl sulfate complex for local administration (dosage schedule: one 25,000-unit vaginal tablet (SPA-S-222) daily for 6 days). Microbiological examination revealed an 88.6% cure rate (samples tested negative) at the end of treatment and a 90.9% cure rate 30 days after cessation of treatment. In addition, the clinical symptoms observed at the beginning of treatment disappeared rapidly and the patients showed great clinical improvement under the present therapy. Both local and systemic tolerance of the preparation used were excellent.

Topics: Administration, Intravaginal; Adult; Candidiasis, Vulvovaginal; Female; Humans; Mepartricin; Middle Aged; Polyenes; Sodium Dodecyl Sulfate

Topics: Adolescent; Adult; Candidiasis, Vulvovaginal; Drug Evaluation; Female; Humans; Mepartricin; Middle Aged; Polyenes; Sodium Dodecyl Sulfate

Acute toxicity and absorption data of a soluble complex of mepartricin with sodium laurylsulphate (SPA-S-222) active against C. albicans and T. vaginalis are reported. The results demonstrate an improved bioavailability with respect to the insoluble substance. Preliminary clinical trials proved the good tolerance of the substance and its effectiveness in oral treatment of vaginal trichomoniasis.

Topics: Administration, Oral; Animals; Candidiasis, Vulvovaginal; Drug Synergism; Female; Injections, Intravenous; Mepartricin; Mice; Polyenes; Rabbits; Rats; Sodium Dodecyl Sulfate; Trichomonas Vaginitis